Hong Kong-listed biopharmaceutical stocks declined at the open, with GenScript Biotech falling more than 15%, Zai Lab dropping over 7%, Tigermed and Junshi Biosciences each losing more than 6%, and RemeGen and InnoCare Pharma each declining over 4%.

Bohai Securities noted that recent AI-driven drug discovery catalysts have been intensive, with the industry focus gradually shifting from model capabilities toward wet-lab validation efficiency and related areas, suggesting investors pay attention to investment opportunities in AI pharma-related sub-sectors such as gene synthesis, protein expression, reagents and consumables, animal models, and clinical trials.

Meanwhile, the 2026 ESMO annual meeting is set to convene soon, with strong clinical data expected to be released, bringing intensive catalysts to the sector, and investors are advised to watch for opportunities in innovative drugs, CXO, and the upstream life sciences supply chain.